Manage episode 273267066 series 2370566
The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. But is also one of medicine’s great paradoxes – a system designed to protect the most sensitive region of the body but, in turn, ends up actively inhibiting the ability to treat disease within that sensitive region.
Bioasis Technologies Inc. (TSX-V.BTI, OTC:BIOAF, Forum) is a biopharmaceutical company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. The Company’s goal is to generate shareholder value by developing and commercializing its proprietary brain delivery technology – XB3 – to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.
In this intriguing podcast, Stockhouse Media’s Dave Jackson was joined by CEO Dr. Deborah Rathjen to talk more about the Company’s amazing XB3 platform, its landmark partnership with the Chiesi Global Rare Diseases Group, and all the things Bioasis shareholders and investors should be watching for in the upcoming months.